Keywords

Suggestions

Reference

What's New

          SIGN UP

          Join our health care panel today.
          Share your insights and earn honorarium.

          for MDs

          MDThink makes you smarter

          Epacadostat in Combination with Ppembrolizumab demonstrates Durable Responses in Patients with Advanced Melanoma

          0
          Print
          15472524 - melanoma

          The European Society for Medical Oncology (ESMO) published an abstract containing new and updated data from the ongoing Phase 1/2 ECHO-202 trial that evaluated epacadostatin combination with the anti-PD-1 KEYTRUDA® (pembrolizumab) in patients with advanced melanoma.

          Across all efficacy-evaluable advanced melanoma patients, median PFS was 12.4 months, with PFS rates of 70%, 54%, and 50% at 6 months, 12 months, and 18 months respectively. In patients who were treatment-naïve for advanced disease, median PFS has not been reached, with landmark PFS rates of 68%, 52% and 51% at 6 months, 12 months, and 18 months respectively.

           

          The combination drug was also well-tolerated. The most common TAEs were fatigue (39%), rash (33%), pruritus (27%), and arthralgia (16%). Grade ≥3 TRAEs were observed in 17% patients; the most common were increased lipase (n=4), rash (n=3), and increased amylase (n=2). Three patients discontinued for reasons of treatment-related adverse events, but there were no treatment-related deaths.

          The abstract can be accessed on the ESMO Congress website at http://esmo.org/Conferences/ESMO-2017-Congress

          Updated data from ECHO-202 will be highlighted in an oral presentation on 09th Sept, 2017 at the ESMO 2017 Congress in Madrid, Spain. The manufacturer, Incyte will also host an investor conference call and webcast at 17:00 CET (11:00 a.m. ET) on 9 September 2017.

          Ref: https://www.afp.com/en/news/1314/new-data-epacadostat-combination-keytrudar-pembrolizumab-demonstrate-durable-responses-patients-advanced


          Location :
          Source : Link

          34 total views, 1 views today

          TwitterFacebookGoogle+LinkedIn
          0

          comments

          Leave a Reply

          Popular News

          Chat []

          Login

          Lost your password?

          VERIFIED & SECURED SSL VERIFIED & SECURED SSL: Secure Socket Layer